292135-78-5 | Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-1-oxido-4-pyridinyl)-4-(difluoromethoxy)-

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$39.00	$27.00
2mg	95%	in stock	$56.00	$39.00
5mg	95%	in stock	$81.00	$57.00
25mg	95%	in stock	$95.00	$66.00
50mg	95%	in stock	$115.00	$80.00
100mg	95%	in stock	$140.00	$98.00
250mg	95%	in stock	$283.00	$198.00
1g	95%	in stock	$1,023.00	$716.00

Description

• Catalog Number: AB36817
• Chemical Name: Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-1-oxido-4-pyridinyl)-4-(difluoromethoxy)-
• CAS Number: 292135-78-5
• Molecular Formula: C17H14Cl2F2N2O4
• Molecular Weight: 419.2069
• MDL Number: MFCD04112984
• SMILES: FC(Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)c[n+](cc1Cl)[O-])F

Computed Properties

• Complexity: 645
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 27
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 6
• XLogP3: 4.8

Literature

• Simultaneous quantitation of IC87114, roflumilast and its active metabolite roflumilast N-oxide in plasma by LC-MS/MS: application for a pharmacokinetic study.

  Journal of mass spectrometry : JMS 20121201

• The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice.

  Diabetologia 20121001

• Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro.

  British journal of pharmacology 20120801

• Sensitive quantification of roflumilast and roflumilast N-oxide in human plasma by LC-MS/MS employing parallel chromatography and electrospray ionisation.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120415

• Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide.

  British journal of pharmacology 20120301

• Roflumilast-N-oxide induces surfactant protein expression in human alveolar epithelial cells type II.

  PloS one 20120101

• Pharmacokinetic evaluation of roflumilast.

  Expert opinion on drug metabolism & toxicology 20111201

• Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study.

  International journal of clinical pharmacology and therapeutics 20110801

• Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide.

  Journal of clinical pharmacology 20110401

• No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine.

  Journal of clinical pharmacology 20110401

• Chronopharmacology of roflumilast: a comparative pharmacokinetic study of morning versus evening administration in healthy adults.

  Chronobiology international 20101001

• Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.

  Clinical pharmacokinetics 20100901

• A phosphodiesterase 4 inhibitor, roflumilast N-oxide, inhibits human lung fibroblast functions in vitro.

  Pulmonary pharmacology & therapeutics 20100801

• Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects.

  British journal of clinical pharmacology 20091001

• The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.

  Journal of clinical pharmacology 20090401

• Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide.

  International journal of clinical pharmacology and therapeutics 20090401

• Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide.

  Journal of clinical pharmacology 20081101

• Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability.

  British journal of pharmacology 20071001

• Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast.

  Journal of clinical pharmacology 20070501

• Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis.

  Clinical pharmacokinetics 20070101

• Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide.

  Clinical pharmacokinetics 20070101

• Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects.

  Journal of clinical pharmacology 20061001